The short answer
A harmful guar-gum–glimepiride interaction has not been established. Guar gum has shown mixed effects on glucose in small studies, so medicinal-dose products deserve review and glucose monitoring rather than an assumption that they always cause low blood sugar.
What this answer covers
Guar gum supplements with oral glimepiride. Studies of diet-treated diabetes or a different sulfonylurea remain indirect.
- Supplement or preparation
- Guar gum
- Medication ingredient
- glimepiride
The glucose findings are mixed
A controlled phase in patients using oral diabetes medicines found no significant difference in fasting glucose or glycosylated hemoglobin. A smaller study in diet-treated patients reported improvement. Neither establishes an added hypoglycemia rate for glimepiride.
A related drug study is not this combination
A small trial with glipizide found no significant change in overall exposure despite some early glucose and insulin differences. Glipizide and glimepiride are separate medicines. That result cannot prove safety or a timing rule for your prescription.
Review concentrated products and food changes
The amount and formulation in a supplement may differ from ordinary food use. Tell your clinician when adding a medicinal-dose fiber product or making major dietary changes, especially if glucose readings are already low or variable.
There is no established protective interval
The studies do not show that a particular number of hours prevents low blood sugar with this pair. Continue glimepiride with the prescribed meal and use your clinician’s monitoring plan rather than adjusting the dose on your own.
Evidence and practical considerations
Side effects & toxicity
A harmful guar-gum–glimepiride interaction has not been established. Guar gum has shown mixed effects on glucose in small studies, so medicinal-dose products deserve review and glucose monitoring rather than an assumption that they always cause low blood sugar.
- Exact scope
- Guar gum supplements with oral glimepiride. Studies of diet-treated diabetes or a different sulfonylurea remain indirect. with Oral glimepiride tablets for type 2 diabetes.
- Medication form and route
- oral
What remains uncertain
- No quantified exact-pair risk or protective spacing interval is established. Original-source access and population limitations are documented individually.
Factors that may matter: Exact preparation and amount; Other glucose-lowering treatment; Meal schedule, kidney function and glucose readings.
Read the supporting source summaries
Source 1: Current U.S. regulatory product labeling
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults with type 2 diabetes using oral glimepiride.
Glimepiride can cause severe hypoglycemia. Nicotinic acid is listed among agents that may reduce glucose control. The specified four-hour-before instruction applies to colesevelam.
How this applies: Exact medication labeling provides administration and monitoring context, not proof of untested supplement effects.
The label does not establish every botanical interaction. Colesevelam instructions cannot be transferred to charcoal, glucomannan or other supplements.
Source 2: Original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 39 patients with poorly controlled type 2 diabetes using oral glucose-lowering medicines.
The controlled phase did not show a between-group difference in fasting glucose or glycosylated hemoglobin.
How this applies: Preserves a null clinical result rather than assuming uniform glucose lowering.
Older study without documented glimepiride co-use; longer open observations cannot replace the controlled comparison.
Source 3: Original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 15 diet-treated patients with type 2 diabetes.
Reported improved glycemic control during guar treatment.
How this applies: Shows possible glucose effects in a different treatment setting, not a measured exact-pair adverse interaction.
Small study without concurrent diabetes medication; cannot quantify hypoglycemia during glimepiride use.
Source 4: Original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Ten healthy volunteers.
No significant difference in eight-hour drug exposure; early glucose and insulin responses differed.
How this applies: Avoids extrapolating fiber effects uniformly across sulfonylureas.
Glipizide is a different medicine. Small acute study is not a glimepiride safety or spacing trial.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Initial source-checked research draft. Exact preparations, contrary findings and study limitations documented; clinical review not recorded. | |
| Research summary published |
Article revision: dc0801391d4a856d
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.